Objectives: To assess the long-term safety and efficacy of a sirolimus-eluting stent with bioresorbable polymer (BP-SES; Ultimaster), in comparison to a benchmark everolimuseluting, permanent polymer stent (PP-EES; Xience), in a prespecified subgroup of patients with multivessel coronary artery disease (MVD) enrolled in the CENTURY II trial.
| INTRODUCTION
In recent years, the use of coronary stenting in high-risk subgroups, like multivessel disease (MVD) patients, has increased. The treatment of MVD patients, by percutaneous coronary intervention (PCI), however, is still challenging. These patients usually have more risk factors and comorbidities (e.g., diabetes), as well as overall less favorable long-term outcomes. Moreover, the PCI in MVD patients is often more complex and associates with higher procedural risk. 1 Choosing the most suitable revascularization strategy for MVD patients requires careful evaluation of both patient and lesion status. The available evidence suggests that in MVD patients without diabetes and/or with low-anatomical complexity, PCI, and coronary artery bypass grafts (CABG) achieve similar long-term outcomes with respect to survival and the composite clinical outcomes. In MVD patients with intermediate-tohigh anatomical complexity, however, evidence from large studies implicates CABG as still the preferred choice over PCI in terms of reducing mortality and risk of other serious adverse events. 2 The application of antiproliferative drugs onto bare metal stent scaffolds has improved PCI outcomes with respect to restenosis and the need for repeat interventions. 3, 4 Less favorable long-term safety profile, that is, higher risk of (very) late stent thrombosis (ST), 5 however, challenged these initially promising results. Due to its association with chronic inflammatory reactions, delayed arterial healing, poor re-endothelialisation and positive remodeling, 6 permanent polymer (PP) coating of first generation drugeluting stents (DES) became one of the prime targets for redesign. Consequently, several more advanced drug-carriers were developed, including bioresorbable polymeric carriers (BP) and biocompatible PP variants, as well as nonpolymeric stent surfaces. 7 In the CENTURY II (Clinical Evaluation of New TerUmo drug-elUting coRonary stent system in the treatment of patients with coro-narY artery disease) trial, the Ultimaster sirolimus-eluting BP stent (BP-SES; with abluminal, gradient polymer coating) was shown to be noninferior to the Xience PP everolimus-eluting stent (PP-EES; with circumferential, biocompatible polymer coating) in terms of freedom from target lesion failure (TLF: a composite of cardiac death, target vessel-related myocardial infarction [MI] and clinically driven target lesion revascularization [TLR]), in total study population, at 9 months follow-up (primary endpoint). 8 Good clinical performance of the two stents was recently confirmed also for the long-term, 5-year followup period. 9 In this manuscript, we report the 5-year clinical outcomes of a subgroup of the original CENTURY II trial, consisting of patients diagnosed with MVD at the time of randomization.
| METHODS

| Study design and patients
CENTURY II is a prospective, randomized, single-blind, controlled, noninferiority, multicentre, clinical trial of BP-SES (Ultimaster, Terumo Corporation, Japan) and PP-EES (Xience, Abbott Vascular; study registration number: UMIN000006940), involving 58 enrolling centers (see list in Supporting Information) from Europe, Japan, and South Korea. Out of 1,119 patients, 456 (40.8%) were diagnosed at the time of study entry with MVD and during randomization, that was stratified for this characteristic, allocated to treatment with either BP-SES (n = 225) or PP-EES (n = 231; Figure 1 ). MVD was defined as the presence of >50% diameter stenosis in two or three major epicardial coronary vessels or bypass grafts (as measured by caliper method or coronary angiography online). Analysis of this prespecified MVD subgroup was done using the intention to treat (ITT) approach. Detailed CENTURY II study design and methods have been described elswhere. 8 In brief, patients with ischemic heart disease due to stenotic lesions of coronary arteries with reference vessel diameter suitable for treatment with stents ≥2.5 and ≤4.0 mm (≤3.5 mm in Japan) were eligible. Patients were randomly (1:1) assigned to PCI with either BP-SES or PP-EES. Randomization was balanced (stratified) for diabetes mellitus, high-risk acute coronary syndrome, and MVD. All patients had to provide a signed written informed consent. The study complied with the Declaration of Helsinki and was approved at each participating center by institutional review board and competent authority of each participating country.
| Procedures
All coronary interventions were performed according to standard hospital practice, while all postrandomization procedural decisions were left at operators' discretion. Dual antiplatelet therapy (DAPT) was recommended for at least 6 months. Clinical follow-up was scheduled at 1, 4, 9 months, and yearly until the final 5-year control visit.
| Data management and quality assurance
A data monitoring committee (DMC) was responsible for the review of all data and identification of potential safety issues. An independent clinical event committee (CEC) reviewed and adjudicated all major endpoint-related adverse and bleeding events. All data on case report forms were 100% verified on-site versus source documents.
Members of DMC and CEC were blinded to patient assignment, while investigators and study personnel were not.
| Study devices
Detailed technical description of the Ultimaster (BP-SES) and its' comparator device Xience (PP-EES) have been previously reported. 8 Briefly, Ultimaster uses a thin strut (80 μm) cobalt-chromium platform, with an abluminal gradient bioresorbable polymer coating, while Xience (PP-EES) platform is also based on cobalt-chromium alloy with PP coating.
| Endpoints and definitions
The primary endpoint of CENTURY II study was freedom from target 
| Statistical analysis
The CENTURY II randomized trial was statistically powered for noninferiority of BP-SES compared to PP-EES regarding the primary endpoint of freedom from TLF in the total population at 9-months. The TLF-free rate was 95.64% for BP-SES and 95.09% for PP-EES, dem- . Dichotomous clinical endpoints were tested using the chi-squared test. The Kaplan-Meier method was used to estimate event rates for time-to-event outcomes, while the data were compared using the log-rank test. To explore whether TLF with BP-SES versus PP-EES was consistent across categories of clinical, procedural, or lesion characteristics, logistic regression analysis with interaction testing was performed. All analyses were performed, using the SAS software, version 9.4 (SAS Institute, Inc., Cary, NC).
| RESULTS
| Patient and procedural characteristics
Four hundered and fifty-six MVD patients were assigned to either BP-SES (n = 225) or PP-EES (n = 231) treatment-arm ( Figure 1 ). This subgroup constituted 40.8% of the total study population (n = 1,119). Lesion localization was similar between the study groups. More than 80% of lesions were classified as type B2 or C (ACC/AHA classification), while 12.7% represented bifurcation lesion. The frequency of ostial localization as well as the level of lesion calcification did not differ between the two treatment arms. Only significantly higher presence of chronic total occlusion (CTO) lesions was noted in BP-SES treated patients (Table 2 ). Regarding the procedural aspects, the frequency of pre-and post-dilatations, and utilized access sites were similar among the two arms, radial artery being the most frequently used approach (69.1%). Mean total implanted stent number and the total length of the implanted stents per patient were 1.9 ± 1.0 and 37.0 ± 21.3 mm, respectively, and were similar among the two arms.
Overall, baseline lesion and procedural characteristics were largely alike ( Table 2) . Table 3 . Proportion of patients on DAPT did not differ between the two treatment arms during the entire follow-up period.
| Medium-and long-term clinical outcomes
Throughout 5-year follow-up period, the rate of TLF composite endpoint was similar among the two treatment arms: 5.3 versus 7.8% at 1-year (p = .29; Table 4 ) and 10.2 versus 13.4% at 5 years (p = .29; Table 5 ) in BP-SES and PP-EES arm, respectively ( Figure 2 ). The TVF composite endpoint rates were similar in two arms at 1-and 5-years, as was the incidence of clinically indicated TLR at both time points (Tables 4 and 5 ). The incidence of all non-TVR and any revascularization was significantly higher in PP-EES arm only at 1-year follow- in BP-SES arm compared to 10.8% in PP-EES arm (p = .12; Table 5 ).
Five-year rates of POCE were 27.1% in BP-SES versus 34.2% in PP-EES (p = .10; Table 5 ).
At 1 year follow-up, no difference in bleeding rate between the two groups was noted (Table 4) , however, a statistically significant higher rate of bleeding incidence at 5-years follow-up was observed in BP-SES arm ( Table 5 ). Finally, the analysis of possible predictors of TLF, including diabetes, Charlson comorbidity index, Syntax score, and complete versus incomplete revascularization of the coronary tree is shown in Figure 5 . The risk of TLF after treatment with BP-SES compared with PP-EES did not differ across categories of these predictors (p for interaction >.05).
| DISCUSSION
To the best of our knowledge, the presented data represents unique clin- (BP-SES) system. This includes reports of favorable outcomes in general 8, 9 and specific subpopulations, like STEMI patients, 21 bifurcations, 22 long lesions, 23 and small vessels. 24 Our analysis of TLF predictors implies that patient, lesion, and procedural complexity exert little impact on TLF in the studied context ( Figure 5 ). Particularly interesting is that relative risk of TLF does not seem to be impacted by the decision to perform complete over incomplete coronary tree revascularization. This finding is at odds with current trends, favoring the complete approach as the more optimal modus operandi. Potential explanation could be that physiological assessment of stenosis in untreated vessels was determining factor for deferring revascularization, leading as such to similar outcomes. Caution, however, needs to be taken with interpretation of these findings, as they derive from a relatively small study subset of patients and as such warrant further analysis.
Finally, bleeding rates were comparable at 1 year follow up while a higher cumulative bleeding incidence was noted in BP-SES treated MVD patients at 5 years. Considering no difference in DAPT use over the 5-year follow-up period, a possible explanation can be that higher proportion of patients with high-risk for bleeding, including prevalence of oral anticoagulant users, patients with traumas, and/or comorbidities was acquired through 5 years follow-up in the BP-SES group.
| LIMITATIONS
Although MVD patients did constitute a balanced, predefined subgroup of the CENTURY II trial, this substudy was not powered to demonstrate non-inferiority of BP-SES to PP-EES. Therefore, herein
presented results are only hypothesis-generating and future studies, with sufficient power, are needed to corroborate these interesting findings. Also notable is that the angiographic complexity of MVD patient in this CENTURY II substudy was relatively low (with baseline SYNTAX score between 12 and 13 for both groups). Therefore, our results cannot be extrapolated to all MVD patients seen in everyday practice, that are treated by either PCI or CABG. Moreover, even though DMC and CEC members were blinded for patients' assignment, logistical factors prevented blinding of study personnel. While this factor certainly warrants caution, we believe that its impact on reported findings should not be significant, as to cast doubt on the overall conclusions of the study.
| CONCLUSION
Our study reveals, that throughout the 5-year follow-up period, sirolimus-eluting bioresorbable polymer Ultimaster stent (BP-SES), displays similarly good long-term safety and efficacy profile as the everolimus-eluting permanent polymer Xience stent (PP-EES), in the treatment of MVD patients.
